§
Luxuse
Patent Intelligence
Sign In
Patent US3875165A successfully refreshed from Google Patents.
← Back to Patent Explorer
US3875165A Expired / Lapsed US ⏱️ 0.0 years remaining

(4-Quinolylamino)-(N-piperidyl)benzamides and N-{8 (quinolylamino)-benzoyl{9 piperidines

Assignee: John Wyeth and Brother Ltd
•
Filing: 1973-02-22
•
Granted: 1975-04-01
•
Expires: 1993-02-22
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The disclosure describes new 4-aminoquinoline derivatives of general formula AND THEIR ACID ADDITION SALTS, WHERE X is a halogen atom or a trifluoromethyl group, Z is a hydrogen atom or a defined substituent, R is group of the formula -R3N-A-NR1R2 (II), where A in formula II is a chain of 1 to 5 methylene groups which may be substituted with alkyl, the ring in formula IIIa and IIIb is a piperidine or pyrrolidine ring that may be substituted with alkyl and R1, R2 and R3 represent hydrogen or certain defined substituents. The new 4-aminoquinoline derivatives show anti-malarial activity and, in some cases, shows one or more of the following activities: antiinflammatory activity, anti-hypertensive activity, antitrichomonal activity, inhibition of blood platelet aggregation, anti-ulcer activity and activity against allergic asthma.

Inventors

  • 👤 John Leheup Archibald
  • 👤 John Terence Arnott Boyle
  • 👤 John Christopher Saunders

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-31 18:30
CPC Classifications
C; C07; C07D; C07D215/00; C07D215/02; C07D215/16; C07D215/38; C07D215/42; C07D215/44

Claims Analysis

Total Claims: 13
Claim 1
Independent Claim 12 words
A COMPOUND SELECTED FROM THE GROUP CONSISTING OF BASES HAVING THE FORMULA
Claim 2
Dependent Claim 12 words
A COMPOUND SELECTED FROM THE GROUP CONSISTING OF BASES HAVING THE FORMULA
Claim 3
Dependent Claim 17 words
A compound according to claim 1, which is 3-(p-(7-chloro-4-quinolylamino)benzamido)-1-ethyl-piperidine or a pharmaceutical acceptable acid addition salt thereof.
Claim 4
Dependent Claim 18 words
A compound according to claim 1, which is 1-(p-(7-chloro-4-quinolylamino)-benzoyl)-4-dimethylamino piperidine or a pharmaceutically acceptable acid addition salt thereof.
Claim 5
Dependent Claim 17 words
A compound according to claim 1, which is 4-(p-(7-chloro-4-quinolylamino)-benzamido)-1-methyl-piperidine or a pharmaceutically acceptable acid addition salt thereof.
Claim 6
Dependent Claim 17 words
A compound according to claim 1, which is 1-butyl-4-(4-(7-chloro-4-quinolylamino)-benzamido)-piperidine or a pharmaceutically acceptable acid addition salt thereof.
Claim 7
Dependent Claim 17 words
A compound according to claim 1, which is 1-(4-(7-chloro-4-quinolylamino)-benzoyl)-4-diethylaminopiperidine or a pharmaceutically acceptable acid addition salt thereof.
Claim 8
Dependent Claim 17 words
A compound according to claim 1, which is 3-(2-chloro-4-(7-chloro-4-quinolylamino)-benzamido)-1-ethylpiperidine or a pharmaceutically acceptable acid addition salt thereof.
Claim 9
Dependent Claim 17 words
A compound according to claim 1, which is 1-butyl-4-(2-chloro-4-(7-chloro-4-quinolylamino)benzamido)piperidine or a pharmaceutically acceptable acid addition salt thereof.
Claim 10
Dependent Claim 17 words
A compound according to claim 1, which is 3-(3-(7-chloro-4-quinolylamino)-benzamido)-1-ethylpiperidine or a pharmaceutically acceptable acid addition salt thereof.
Claim 11
Dependent Claim 17 words
A compound according to claim 1, which is 4-(7-chloro-4-quinolylamino)-N-(1-ethyl-4-piperidyl)benzamide or a pharmaceutically acceptable acid addition salt thereof.
Claim 12
Dependent Claim 17 words
A compound according to claim 1, which is 3-dimethylamino-1-(4-(7-chloro-4-quinolylamino)benzoyl)-piperidine or a pharmaceutically acceptable acid addition salt thereof.
Claim 13
Dependent Claim 18 words
A compound according to claim 1, which is 4-(7-chloro-4-quinolylamino)-N-(1-ethyl-3-piperidyl)-3-methoxy benzamide or a pharmaceutically acceptable acid addition salt thereof.

References Cited (Backward Citations)

US3132145A Cited
US3644368A Cited
US3632761A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1978-03-31 1978-09-30 1979-04-01 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1982-03-31 1982-09-30 1983-04-01 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1986-03-31 1986-09-30 1987-04-01 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag